Literature DB >> 28420285

Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.

Yagmur Akdag Cayli1, Selma Sahin1, Francesca Buttini2, Anna Giulia Balducci2, Serena Montanari2, Imran Vural1, Levent Oner1.   

Abstract

OBJECTIVE: This study aimed to design and characterize an inhalable dry powder of ciprofloxacin or levofloxacin combined with the mucolytics acetylcysteine and dornase alfa for the management of pulmonary infections in patients with cystic fibrosis.
METHODS: Ball milling, homogenization in isopropyl alcohol and spray drying processes were used to prepare dry powders for inhalation. Physico-chemical characteristics of the dry powders were assessed via thermogravimetric analysis, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR), X-ray diffractometry and scanning electron microscopy. The particle size distribution, dissolution rate and permeability across Calu-3 cell monolayers were analyzed. The aerodynamic parameters of dry powders were determined using the Andersen cascade impactor (ACI).
RESULTS: After the micronization process, the particle sizes of the raw materials significantly decreased. X-ray and DSC results indicated that although ciprofloxacin showed no changes in its crystal structure, the structure of levofloxacin became amorphous after the micronization process. FT-IR spectra exhibited the characteristic peaks for ciprofloxacin and levofloxacin in all formulations. The dissolution rates of micro-homogenized and spray-dried ciprofloxacin were higher than that of untreated ciprofloxacin. ACI results showed that all formulations had a mass median aerodynamic diameter less than 5 μm; however, levofloxacin microparticles showed higher respirability than ciprofloxacin powders did. The permeability of levofloxacin was higher than those of the ciprofloxacin formulations.
CONCLUSION: Together, our study showed that these methods could suitably characterize antibiotic and mucolytic-containing dry powder inhalers.

Entities:  

Keywords:  Dry powder inhaler; ciprofloxacin; cystic fibrosis; levofloxacin; mucolytic; permeability

Mesh:

Substances:

Year:  2017        PMID: 28420285     DOI: 10.1080/03639045.2017.1318902

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  4 in total

1.  Pulmonary Targeting of Levofloxacin Using Microsphere-Based Dry Powder Inhalation.

Authors:  Turki Al Hagbani; Bhavya Vishwa; Amr S Abu Lila; Hadil Faris Alotaibi; El-Sayed Khafagy; Afrasim Moin; Devegowda V Gowda
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-30

2.  In Vitro Synergism of Colistin and N-acetylcysteine against Stenotrophomonas maltophilia.

Authors:  Nagaia Ciacci; Selene Boncompagni; Felice Valzano; Lisa Cariani; Stefano Aliberti; Francesco Blasi; Simona Pollini; Gian Maria Rossolini; Lucia Pallecchi
Journal:  Antibiotics (Basel)       Date:  2019-07-25

Review 3.  Continuous Formulation Approaches of Amorphous Solid Dispersions: Significance of Powder Flow Properties and Feeding Performance.

Authors:  Edina Szabó; Balázs Démuth; Dorián László Galata; Panna Vass; Edit Hirsch; István Csontos; György Marosi; Zsombor K Nagy
Journal:  Pharmaceutics       Date:  2019-12-05       Impact factor: 6.321

Review 4.  Multifunctional Nanocarriers for Lung Drug Delivery.

Authors:  Jorge F Pontes; Ana Grenha
Journal:  Nanomaterials (Basel)       Date:  2020-01-21       Impact factor: 5.076

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.